| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Beihai Gofar Chuanshan Biological Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.06 |
| 52 Week High | CN¥5.45 |
| 52 Week Low | CN¥3.20 |
| Beta | -0.35 |
| 1 Month Change | -16.63% |
| 3 Month Change | -13.06% |
| 1 Year Change | -1.22% |
| 3 Year Change | -39.49% |
| 5 Year Change | -28.65% |
| Change since IPO | -28.10% |
Recent News & Updates
Shareholder Returns
| 600538 | CN Chemicals | CN Market | |
|---|---|---|---|
| 7D | -1.9% | -0.8% | 0.06% |
| 1Y | -1.2% | -19.9% | -16.1% |
Return vs Industry: 600538 exceeded the CN Chemicals industry which returned -19.9% over the past year.
Return vs Market: 600538 exceeded the CN Market which returned -16.1% over the past year.
Price Volatility
| 600538 volatility | |
|---|---|
| 600538 Average Weekly Movement | 6.2% |
| Chemicals Industry Average Movement | 7.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.2% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 600538's share price has been volatile over the past 3 months.
Volatility Over Time: 600538's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 463 | Bin Pan Li | www.gofar.com.cn |
Beihai Gofar Chuanshan Biological Co., Ltd. engages in the production and distribution of pharmaceutical products in China. The company offers various medicines and medical devices; and produces and sells pearl eye drops, pearl powder, nacre powder, weiweining granules, compound Kumu Xiaoyan tablets, etc. under the Haibao brand.
Beihai Gofar Chuanshan Biological Co., Ltd. Fundamentals Summary
| 600538 fundamental statistics | |
|---|---|
| Market cap | CN¥2.13b |
| Earnings (TTM) | -CN¥92.02m |
| Revenue (TTM) | CN¥355.15m |
6.0x
P/S Ratio-23.1x
P/E RatioIs 600538 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600538 income statement (TTM) | |
|---|---|
| Revenue | CN¥355.15m |
| Cost of Revenue | CN¥272.45m |
| Gross Profit | CN¥82.70m |
| Other Expenses | CN¥174.72m |
| Earnings | -CN¥92.02m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 23.29% |
| Net Profit Margin | -25.91% |
| Debt/Equity Ratio | 0.8% |
How did 600538 perform over the long term?
See historical performance and comparison